Effective Decedmber 9th, 2004
FORM 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON DC 20549

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

MEDISCIENCE TECHNOLOGY CORPORATION
(EXACT NAME OF REGISTRANT AS SPECIFIED ON CHARTER)

NEW JERSEY
0-7405
22-1937826
(State of Incorporation)(IRS Employer Identification No.)(Commission File No.)

1235 Folkestone Way, P.O. Box 598, Cherry Hill, New Jersey 08003


(856) 428 7952


Registrant's telephone number. Including area code

  


(Former Address, if changed, since last report)

 

Item 7.01 Regulation FD Disclosure.

On December 9, 2004, Mediscience Technology Corp. issued a press release. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein solely for purposes of this Item 7.01.

In accordance with General Instruction B.2 of Form 8-K, the information set forth in this Item 7.01, including Exhibit 99.1, is furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in this Item 7.01 shall not be deemed an admission as to the materiality of any information in this report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

December 9, 2004 Mediscience Technology Corp.
By: Peter Katevatis

Name: Peter Katevatis
Title: Chief Executive Officer

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits.  Exhibit No.

99.1
Description

Press Release

Exhibit 99.1

MEDISCIENCE TECHNOLOGY CORP. ANNOUNCES COMPLETION OF DEVELOPMENT OF ITS OPTICAL BIOPSY CANCER DIAGNOSTIC RATIOMETER AND SUBMISSION TO THE FDA OF THE PRE-IDE BRIEFING MATERIALS

CHERRY HILL, N.J.--(BUSINESS WIRE)--Dec. 9, 2004-- Mediscience Technology Corp. (OTC:MDSC) announced today that its wholly owned New York subsidiary, Medi-Photonics Development LLC, has completed development of its Optical Biopsy Cancer Diagnostic Ratiometer(TM) for the molecular screening and detection of cancer and physiological change. The Company also announced that it had submitted its Pre-IDE briefing materials to the United States Food and Drug Administration (FDA).

President and Chief Operating Officer Michael Engelhart stated "The timely completion of our Optical Biopsy Cancer Diagnostic Ratiometer should provide us with a clear path for our applications platform commercialization in the early screening, detecting and diagnosing of cancers of the cervix, mouth, esophagus and gastro intestinal tract." Engelhart added "We have submitted our initial Pre-IDE briefing materials for early screening and detection of abnormalities including cancer of the cervix with the FDA for marketing in the U.S."

Safe Harbor Statement: To the extent that any statements made in this press release contain information that is not historical, these statements are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, among others, the availability of financing, the Company's ability to implement its long-range business plan for various applications of its technology, the Company's ability to enter into agreements with any necessary marketing and/or distribution partners, the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the Company' technology, and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.